Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

199 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Human CD8 and CD4 T cell epitopes of epithelial cancer antigens.
Sato N, Nabeta Y, Kondo H, Sahara H, Hirohashi Y, Kashiwagi K, Kanaseki T, Sato Y, Rong S, Hirai I, Kamiguchi K, Tamura Y, Matsuura A, Takahashi S, Torigoe T, Ikeda H. Sato N, et al. Among authors: kanaseki t. Cancer Chemother Pharmacol. 2000;46 Suppl:S86-90. doi: 10.1007/pl00014057. Cancer Chemother Pharmacol. 2000. PMID: 10950155
Natural antigenic peptides from squamous cell carcinoma recognized by autologous HLA-DR8-restricted CD4+ T cells.
Kondo H, Sahara H, Miyazaki A, Nabeta Y, Hirohashi Y, Kanaseki T, Yamaguchi A, Yamada N, Hirayama K, Suzuki M, Hamuro J, Torigoe T, Takahashi N, Kohama GI, Ikeda H, Sato N. Kondo H, et al. Among authors: kanaseki t. Jpn J Cancer Res. 2002 Aug;93(8):917-24. doi: 10.1111/j.1349-7006.2002.tb01338.x. Jpn J Cancer Res. 2002. PMID: 12716470 Free PMC article.
Epigenetic inactivation of class II transactivator (CIITA) is associated with the absence of interferon-gamma-induced HLA-DR expression in colorectal and gastric cancer cells.
Satoh A, Toyota M, Ikeda H, Morimoto Y, Akino K, Mita H, Suzuki H, Sasaki Y, Kanaseki T, Takamura Y, Soejima H, Urano T, Yanagihara K, Endo T, Hinoda Y, Fujita M, Hosokawa M, Sato N, Tokino T, Imai K. Satoh A, et al. Among authors: kanaseki t. Oncogene. 2004 Nov 25;23(55):8876-86. doi: 10.1038/sj.onc.1208144. Oncogene. 2004. PMID: 15467734
A potent immunogenic general cancer vaccine that targets survivin, an inhibitor of apoptosis proteins.
Idenoue S, Hirohashi Y, Torigoe T, Sato Y, Tamura Y, Hariu H, Yamamoto M, Kurotaki T, Tsuruma T, Asanuma H, Kanaseki T, Ikeda H, Kashiwagi K, Okazaki M, Sasaki K, Sato T, Ohmura T, Hata F, Yamaguchi K, Hirata K, Sato N. Idenoue S, et al. Among authors: kanaseki t. Clin Cancer Res. 2005 Feb 15;11(4):1474-82. doi: 10.1158/1078-0432.CCR-03-0817. Clin Cancer Res. 2005. PMID: 15746049
Immunogenic enhancement and clinical effect by type-I interferon of anti-apoptotic protein, survivin-derived peptide vaccine, in advanced colorectal cancer patients.
Kameshima H, Tsuruma T, Torigoe T, Takahashi A, Hirohashi Y, Tamura Y, Tsukahara T, Ichimiya S, Kanaseki T, Iwayama Y, Sato N, Hirata K. Kameshima H, et al. Among authors: kanaseki t. Cancer Sci. 2011 Jun;102(6):1181-7. doi: 10.1111/j.1349-7006.2011.01918.x. Epub 2011 Apr 24. Cancer Sci. 2011. PMID: 21371173 Free article. Clinical Trial.
199 results